134 related articles for article (PubMed ID: 22258344)
1. Unicentric Castleman disease relapsed after rituximab-CHOP chemotherapy or radiation therapy in an adolescent.
Baek HJ; Kook H; Han DK; Shin MG; Kim HS; Hwang TJ
J Pediatr Hematol Oncol; 2012 Jul; 34(5):e206-8. PubMed ID: 22258344
[TBL] [Abstract][Full Text] [Related]
2. Surgical resection combined with CHOP chemotherapy plus rituximab for a patient with advanced mesenteric diffuse large B cell lymphoma.
Yamaguchi T; Takahashi H; Kagawa R; Takeda R; Sakata S; Nishizaki D; Takamatsu T; Iwasa Y
Hepatogastroenterology; 2008; 55(84):891-4. PubMed ID: 18705290
[TBL] [Abstract][Full Text] [Related]
3. Castleman disease and adenocarcinoma.
Megalakaki A; Evmorfiadis I; Stamouli M; Zakopoulou N; Iacovidou I
J BUON; 2011; 16(4):781-2. PubMed ID: 22331742
[No Abstract] [Full Text] [Related]
4. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
5. Complete remission in 4 patients with human herpesvirus 8-associated multicentric Castleman disease using rituximab and liposomal doxorubicin, a novel chemotherapy combination.
Peker D; Martinez AE; Schwartz MA; Cusnir M
Clin Adv Hematol Oncol; 2012 Mar; 10(3):204-6. PubMed ID: 22402431
[No Abstract] [Full Text] [Related]
6. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
7. Surgical outcome of superficial and deep Castleman disease.
Chen CH; Liu HC; Tung KY; Lee JJ; Liu CL; Liu TP
ANZ J Surg; 2007 May; 77(5):339-43. PubMed ID: 17497971
[TBL] [Abstract][Full Text] [Related]
8. Rituximab CHOP for successful management of diffuse large B-cell lymphoma of the ovary.
Ahbeddou N; Fetohi M; Khanoussi BE; Errihani H
Arch Gynecol Obstet; 2011 May; 283(5):1173-4. PubMed ID: 20957380
[No Abstract] [Full Text] [Related]
9. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
Johnston A; Salles G; Espinouse D; Felman P; André P; Berger F; Coiffier B
Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
12. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report.
Galeotti C; Tran TA; Franchi-Abella S; Fabre M; Pariente D; Koné-Paut I
J Pediatr Hematol Oncol; 2008 Dec; 30(12):920-4. PubMed ID: 19131781
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy and rituximab.
Czuczman MS
Anticancer Drugs; 2001 Jun; 12 Suppl 2():S15-9. PubMed ID: 11508932
[TBL] [Abstract][Full Text] [Related]
14. Rituximab tolerability when given before or after CHOP.
Hannawa IS; Bestul DJ
J Oncol Pharm Pract; 2011 Dec; 17(4):381-6. PubMed ID: 21109616
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
16. Primary lymphoma of the uterus and cervix: two case reports and review of the literature.
Upanal N; Enjeti A
Aust N Z J Obstet Gynaecol; 2011 Dec; 51(6):559-62. PubMed ID: 21923699
[TBL] [Abstract][Full Text] [Related]
17. Cervical unicentric Castleman disease presenting as a neck mass: case report and review of the literature.
Liang J; Newman JG; Frank DM; Chalian AA
Ear Nose Throat J; 2009 May; 88(5):E8. PubMed ID: 19444782
[TBL] [Abstract][Full Text] [Related]
18. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab.
Kurokawa T; Hase M; Tokuman N; Yoshida T
Hematol Oncol; 2011 Mar; 29(1):5-9. PubMed ID: 20552573
[TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab.
Smith SD; Bolwell BJ; Rybicki LA; Kang T; Dean R; Advani A; Thakkar S; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2011 Feb; 46(2):262-6. PubMed ID: 20479706
[TBL] [Abstract][Full Text] [Related]
20. [Intravascular large B-cell lymphoma: an important cause of fever of unknown origin].
Masaki Y; Miki M; Sakai T; Sawaki T; Fukushima T; Umehara H
Brain Nerve; 2011 May; 63(5):435-41. PubMed ID: 21515922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
